Clinical trials: COVID-19 Disease, Severe Form
Covid19, Ventilators, Mechanical
Efficacy of FES Cycling After a Severe Form of COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) affect at late march 2021 more than 127 millions of persons worldwide (including more than 4.5 millions in France…
- Conditions
- Covid19, Ventilators, Mechanical, Respiratory Distress Syndrome
- Trial name
- FESrehabCoV (NCT04841746)
- Testing
- Physical therapy that include a standardized cycling training with functional electrical stimulation, Physical therapy that include a standardized cycling training with no additional functional electrical stimulation
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospices Civils de Lyon
COVID-19 Disease, Severe Form
Senior-COVID-Rea Multicentric Survey
With the spread of COVID-19 epidemic since 2019 in Wuhan, China health plans have to be adapted continuously in response to the emergency.
- Trial name
- SeniorCOVIDRea (NCT04422340)
- Testing
- Group1
- Where
- 7 sites in France
- Volunteers
- 185 people
- Sponsor
- Hospices Civils de Lyon
ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2, Acute Refractory Heart Failure Related to SARS-CoV 2
Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19
The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known.
- Trial name
- ECMO-SARS (NCT04397588)
- Where
- 44 sites in France
- Volunteers
- 761 people
- Sponsor
- Rennes University Hospital
COVID-19
COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
This is a national multicentre observational study with retrospective and prospective data collection to assess the time to hospitalisation of patients with a confirmed diagnosis of SARS-CoV-2 infection receiving treatment with…
- Trial name
- CONDIVIDIAMO (NCT05268601)
- Testing
- Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination
- Where
- Italy
- Volunteers
- 251 people
- Sponsor
- University of Milano Bicocca
Covid19
Involvement of Polymorphonuclear Neutrophils and Platelets in Severe Form of COVID-19
The main objective is to quantify the population of reverse migrating neutrophils in patients with COVID-19.
- Trial name
- NeutroVID (NCT04930757)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19, Vitamin D
Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers
In a blinded randomized clinical trial, which will include health workers (doctors, residents, nurses, stretcher-bearers, technicians, hygiene and cleaning) who are members of the health teams that care for patients with…
- Trial name
- COVID-19 (NCT04535791)
- Testing
- Cholecalciferol
- Where
- Mexico
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Coordinación de Investigación en Salud, Mexico
COVID-19 Pandemic, Obesity
Obesity: an Underappreciate Risk Factor for Severe Form of COVID-19
Our study has the objective of identifying the epidemiological profil of the patients, as well as, the clinical, radiological and prognosis of obese patients with covid 19.
- Trial name
- NCT05771857
- Testing
- Obesity
- Where
- Morocco
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- Mohammed VI University Hospital
Coronavirus Infection
Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, with CoViD-19
The aim of the study is to evaluate two differents regimens of corticosteroids (prednisolone versus dexamethasone) on D28 mortality in patients with CoViD 19 pneumonia requiring oxygen supplementation
- Trial name
- COPreDex (NCT04765371)
- Testing
- DEXAMETHASONE, PREDNISOLONE
- Where
- 8 sites in France
- Volunteers
- 89 people
- Sponsor
- Hôpital NOVO
COVID-19 Disease
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or…
- Trial name
- NCT04969172
- Testing
- Exosomes overexpressing CD24
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Eli Sprecher, MD
COVID-19
Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19
The development of acute respiratory and renal failure of COVID-19 patients is associated with an excessive immune response and hyperproduction of anti-inflammatory cytokines, which leads to impaired endothelial function and a…
- Trial name
- NCT06402279
- Testing
- Efferon CT therapy
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Efferon JSC
COVID-19
Retrospective Study for Identificatiopn of a Link Between Doxycycline and COVID-19 Treatment
A new coronavirus, the third documented animal-to-human passage, emerged in Wuhan , China in the last quarter of 2019. Acne patients on doxycycline escaped seasonal viruses, showing the interest of this antibiotic as a possible…
- Trial name
- DOXY-COVID (NCT05445479)
- Testing
- Doxycycline
- Sponsor
- Nantes University Hospital
Covid19, SARS-CoV Infection
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
This study is a community hospital-based study that will enhance information being obtained in similar studies taking place in France, Denmark, and China.
- Conditions
- Covid19, SARS-CoV Infection, Communicable Disease
- Trial name
- NCT04540484
- Testing
- Screening
- Where
- United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences